HLS Therapeutics Inc
TSX:HLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.2), the stock would be worth CA$3.38 (26% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.7 | CA$4.59 |
0%
|
| 3-Year Average | 1.2 | CA$3.38 |
-26%
|
| 5-Year Average | 1.7 | CA$4.58 |
0%
|
| Industry Average | 3.3 | CA$8.93 |
+95%
|
| Country Average | 2.7 | CA$7.3 |
+59%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
HLS Therapeutics Inc
TSX:HLS
|
143.5m CAD | 1.7 | -8.3 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
101.9B USD | -78.7 | 23.5 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.9B USD | 31.7 | 37.3 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.2B USD | 31 | 36.4 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
47.2B USD | -16.5 | 28.7 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.1B AUD | 6.5 | 34.9 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.6B CNY | 0.8 | 10.9 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
61.7B CNY | 2.6 | 21.8 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9B USD | 2.8 | 22.6 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 6 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
60B HKD | 0.6 | 7.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.7 |
| 70th Percentile | 4.9 |
| Max | 1 402.4 |
Other Multiples
HLS Therapeutics Inc
Glance View
HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The firm is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.
